Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) is currently experiencing a decline in stock price, closing at 54.08 yuan with a drop of 3.41%, indicating it is in a state of underperformance since its IPO [1] Group 1: IPO Details - Baicheng Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on December 20, 2021, with an initial issuance of 27.0417 million shares at a price of 79.60 yuan per share [1] - The stock reached a peak price of 120 yuan on its first trading day, marking the highest price since its listing [1] - The total funds raised from the IPO amounted to 2.153 billion yuan, with a net amount of 1.863 billion yuan after deducting issuance costs, exceeding the original plan by 1.213 billion yuan [1] Group 2: Fund Utilization - The company intended to raise 651 million yuan, which was planned to be used entirely for the headquarters and R&D center project of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. [1] - The total issuance costs for the IPO were 289 million yuan, including underwriting and sponsorship fees of 262 million yuan [1]
百诚医药跌3.41% 2021年上市即巅峰超募12亿